MustGrow Biologics (CSE: MGRO) this morning released further results from ongoing field trials being conducted on its products. The latest results come from Colombia, where the firm was conducting floriculture trials with Gowan Group, an ag solutions firm focused on global agricultural inputs.
The trial itself saw the firms mustard-derived biopesticide tested on another form of fusarium, with results from the program being positive. MustGrow’s product reportedly outperformed both steam sterilization and the untreated check, enabling the disease to be controlled at an application rate of 5 gallons per acre, an economic applicate rate.
Specifically, trials were conducted on soil and vegetal material used to grow carnations from two leading growers in the country. The biopesticide was assessed on both a pre and post treatment basis, with results showing a decrease in fusarium’s population by 99.75%, making it more effective than the traditional method of steam sterilization.
Sponsored · Antimony Resources
Following the positive results of the study, MustGrow and Gowan are continuing to work together to further evaluate the biopesticide, with a focus on the potential impact it can have on the Colombian floriculture market. The region is the largest global producer of carnations and the second largest product of all cut flowers sold worldwide.
MustGrow Biologics last traded at $1.75 on the CSE.
FULL DISCLOSURE: MustGrow Biologics Corp is a client of Canacom Group, the parent company of The Deep Dive. The author has been compensated to cover MustGrow Biologics Corp on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.
